Last reviewed · How we verify
Allergovac depot
Allergovac depot is a Allergen immunotherapy Biologic drug developed by Roxall Medicina España S.A. It is currently in Phase 2 development. Also known as: Allergovac.
Allergen immunotherapy that gradually desensitizes the immune system through repeated exposure to specific allergens in a depot formulation.
Allergovac depot is a subcutaneous immunotherapy used to treat conditions such as allergic rhinoconjunctivitis and rhinitis. It is a gonadotropin-releasing hormone receptor agonist, classified as an agonist drug modality.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Allergovac depot |
|---|---|
| Also known as | Allergovac |
| Sponsor | Roxall Medicina España S.A |
| Drug class | Allergen immunotherapy |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
Allergovac depot works through allergen-specific immunotherapy, exposing patients to controlled amounts of allergens to induce immune tolerance. The depot formulation allows for sustained release of allergen extracts, potentially reducing injection frequency while maintaining therapeutic efficacy.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
- Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense (PHASE2)
- A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea (PHASE1)
- Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites (PHASE1)
- A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica (PHASE1)
- Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allergovac depot CI brief — competitive landscape report
- Allergovac depot updates RSS · CI watch RSS
- Roxall Medicina España S.A portfolio CI
Frequently asked questions about Allergovac depot
What is Allergovac depot?
How does Allergovac depot work?
Who makes Allergovac depot?
Is Allergovac depot also known as anything else?
What drug class is Allergovac depot in?
What development phase is Allergovac depot in?
Related
- Drug class: All Allergen immunotherapy drugs
- Manufacturer: Roxall Medicina España S.A — full pipeline
- Also known as: Allergovac
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing